Whether homodimerization is required for constitutive activity is unknown, although GHSR1a homodimers have been detected
In fact, many of CJC-1295s purported benefits are based on animal studies
Two pieces in your pocket, and you control the timing for once
In October 2023, the FDA designated CJC-1295 and Ipamorelin as Category 2 bulk drug substances effectively prohibiting them from being compounded by licensed pharmacies for human use
The FDA warns that both CJC-1295 and ipamorelin carry risks of immunogenicity (triggering immune responses) and cardiovascular effects, including "increased heart rate and systemic vasodilatory reaction." One clinical trial of CJC-1295 was discontinued following a participants death, though the attending physician believed the event was "unrelated to treatment." Neither CJC-1295 nor ipamorelin is FDA-approved
IGF-1 LR3 Insulin-Like Growth Factor-1 Analog (Long-Acting Research Peptide) Compound Name: Insulin-Like Growth Factor-1 LR3 (IGF-1 LR3) Classification: Research Peptide IGF-1 Analog Description: IGF-1 LR3 is a synthetic analog of insulin-like growth factor-1 engineered with structural modifications that extend stability and reduce binding affinity to IGF-binding proteins in laboratory research environments
